Reprogrammed metabolism is a hallmark of cancer. However, the metabolic dependency of
cancer, from tumour initiation through disease progression and therapy resistance, requires …

Cancer is the leading cause of death worldwide, and its treatment and outcomes have been
dramatically revolutionised by targeted therapies. As the most frequently mutated oncogene …

With only a fraction of patients responding to cancer immunotherapy, a better understanding
of the entire tumor microenvironment is needed. Using single-cell transcriptomics, we chart …

Oncogenic KRAS mutations are the most frequent mutations in human cancer, but most
difficult to target. While sustained proliferation caused by oncogenic KRAS-downstream …

Pancreatic ductal adenocarcinoma (PDAC) is poorly responsive to therapies and
histologically contains a paucity of neoplastic cells embedded within a dense desmoplastic …

ABSTRACT KRAS is the most frequently mutated oncogene in human neoplasia. Despite a
large investment to understand the effects of KRAS mutation in cancer cells, the direct effects …

After decades of efforts, we have recently made progress into targeting KRAS mutations in
several malignancies. Known as the 'holy grail'of targeted cancer therapies, KRAS is the …

Programmed cell death protein 1 (PD-1) ligation delimits immunogenic responses in T cells.
However, the consequences of programmed cell death 1 ligand 1 (PD-L1) ligation in T cells …

Pancreatic stellate cells (PSCs) differentiate into cancer-associated fibroblasts (CAFs) that
produce desmoplastic stroma, thereby modulating disease progression and therapeutic …

Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis largely owing to
inefficient diagnosis and tenacious drug resistance. Activation of pancreatic stellate cells …